Sana Biotechnology to Present at December 2024 Investor Conferences SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 3, 2024.Sana will present a...
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025Announced increased focus on type 1 diabetes and...
Mercury Systems Reports First Quarter Fiscal 2025 Results Q1 FY25 Bookings of $247.7 million; book-to-bill ratio of 1.21Q1 FY25 Revenue of $204.4 million; GAAP net loss of $17.5 million; and adjusted EBITDA of $21.5 millionRecord backlog of $1.3 billion; up 16% year-over-year ANDOVER, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), reported operating results for the first quarter of fiscal year 2025, ended September 27, 2024. “Our first quarter 2025 results were generally as expected, and I am optimistic about our strategic positioning and expectations t...
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells Modified strategy extends expected cash runway into 2026 with potential for multiple data readouts in 2024 and 2025 SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) ...
Nanophase Reports Record Third Quarter Revenue and Profit —Nanophase Reports Q3 Revenue Record at $16.9 Million with Solésence Revenue up 171% YOY —Record $3 Million in Q3 Profit ROMEOVILLE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced record financial results for the third quarter ended September 30, 2024. J...
Mercury Selected by NAVAIR To Continue To Provide Advanced Data Transfer Systems for Navy Aircraft ANDOVER, Mass., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, today announced it was awarded a five-year contract worth as much as $131.3 million from the U.S. Naval Air Systems Command (NAVAIR) to continue providing secure data transfer systems for naval aircraft. Mercury has been delivering (ADTS) and components to the Navy since 2017 to support numerous rotary-wing and fixed-win...
Mercury Systems to Report First Quarter Fiscal Year 2025 Financial Results on November 5, 2024 ANDOVER, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Mercury Systems Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, will release its first quarter fiscal year 2025 financial results after the market close on Tuesday, November 5, 2024. Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on the same day to discuss Mercury's quarterly financial results, business highlights, and outlook. In addition, Company represen...
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website at . ...
Mercury To Provide Upgraded Processing Power for Refueling System on U.S. Air Force’s KC-46A Tanker Fleet ANDOVER, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, announced today that it signed a contract with Boeing to deliver FPGA processor boards that will support an upgraded refueling system on the U.S. Air Force’s KC-46A tanker aircraft fleet. Mercury’s boards are an integral part of the next-generation KC-46A Remote Vision System (RVS) 2.0. Designed for high-sp...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Mercury Introduces New Small Form Factor Digital Signal Processing Module Powered by Altera Agilex FPGAs ANDOVER, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, today announced the expansion of its portfolio of Direct RF digital signal processing products that use Altera™ Agilex FPGAs to detect and process emissions from a wide portion of the electromagnetic spectrum. Direct RF components and modules directly digitize radio frequency signals at the antenna signal frequency...
Sana Biotechnology to Present at September 2024 Investor Conferences SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update. Sana will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024.Sana will present at the 2024 Wells Fargo Healthcare Conference at ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.